- JP-listed companies
- Nxera Pharma Co., Ltd.
- Income statement
Nxera Pharma Co., Ltd.【JP:4565】Income statement
Market cap
¥78.2B
P/E ratio
| 2012/03 | 2013/03 | 2014/03 | 2015/03 | 2016/03 | 2017/03 | 2018/03 | 2018/12 | 2019/12 | 2020/12 | 2021/12 | 2022/12 | 2023/12 | 2024/12 | |
| Revenue | 862 | 1,958 | 2,069 | 3,671 | 8,151 | 18,901 | 6,955 | 2,872 | 9,726 | 8,842 | 17,712 | 15,569 | 12,766 | 28,835 |
| Cost of revenue | - | - | - | - | - | - | - | - | 851 | 761 | 933 | 926 | 646 | 2,284 |
| Gross profit | - | - | - | - | - | - | - | - | 8,875 | 8,081 | 16,779 | 1,118 | 4,369 | 4,297 |
| Gross margin (%) | - | - | - | - | - | - | - | - | - | - | - | |||
| Operating income | - | - | - | -150 | -726 | -158 | -1,069 | -935 | -902 | -483 | -1,158 | -1,095 | -335 | -4,624 |
| Operating expenses | - | - | - | - | - | - | - | - | 3,614 | 3,435 | 3,940 | 4,377 | 9,965 | 16,015 |
| Income before tax | -1,950 | 956 | 737 | 1,301 | -3,297 | 12,483 | -3,702 | -7,243 | 534 | 1,622 | 433 | 1,078 | -10,680 | -4,662 |
| Provision for income taxes | - | - | - | 26 | -1 | 48 | 8 | 3 | -1 | 1 | 1 | 52 | -9 | 7 |
| Net income | -1,954 | 948 | 1,526 | 516 | -1,432 | 9,797 | -2,654 | -5,977 | 1,432 | 1,479 | 1,017 | 382 | -7,193 | -4,838 |
| Earnings per share | -165.15 | 79.97 | 126.65 | 37.51 | -93.6 | 579.97 | -150.19 | -78.4 | 18.7 | 18.77 | 12.53 | 4.68 | -87.18 | -53.92 |
| Diluted EPS | - | - | - | 16.77 | - | 59.24 | - | - | 18.5 | 18.59 | 5.8 | 4.63 | -87.18 | 19.63 |
| Dividend payout ratio (%) | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Dividend per share | - | - | - | 10 | - | - | - | - | - | - | - | - | - | - |